2025 EVENT SITE
WMIF MAIN SITETuesday, September 16, 2025
01:00 PM - 01:40 PM
Emerging Treatments
Over the past few decades, application of immunotherapy in cancer has gone from concept to successful therapy. In particular, manipulation and modification of T-cells has led to exciting results in treating heme malignancies such as acute and chronic leukemia, lymphomas, and multiple myeloma. In particular, CAR-T therapies and bispecific antibodies have shown success in treating several such cancers and have moved from drugs of last resort to earlier lines of therapy. This panel will discuss the progress that has resulted from introduction of highly targeted bispecific antibodies, as well as cell and gene hybrid therapies such as CAR-T, and will address challenges for future developments.
Moderators
Tim Anderson, MD,
Pharmaceutical Analyst, BofA Securities
Alec Stranahan,
SMid-Cap Biotech Analyst, BofA Securities
Speakers
Amir Fathi, MD,
Director, Leukemia Program, Massachusetts General Hospital;
Associate Professor of Medicine, Harvard Medical School
Matthew Frigault, MD,
Massachusetts General Hospital
Connor Johnson, MD,
Assistant Professor of Medicine, Massachusetts General Hospital & Harvard Medical School
Andrew Yee, MD,
Massachusetts General Hospital